AAO 2023: Norlase 4 years later

News
Article

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Oliver Hvidt:

Hello, I'm Oliver Hvidt. I'm the CEO and co-founder of Norlase. We are really excited to be here at AAO 2023. Norlase's journey actually started right here in San Francisco at AAO 2019, where we launched our first laser photocoagulator, the LEAF. Since then, it's been an incredible journey for us. In just 4 short years we've gone on from 1 product to now 3 products in the market and to becoming one of the leading laser manufacturers in the industry. After launching LEAF in 2019, we came out with the LION, the world's first integrated indirect ophthalmoscope and laser in 2020. And last year, we were able to reveal the ECHO, the world's first truly portable and truly affordable pattern laser. We are now in more than 70 different markets worldwide. And we are approaching the delivery of our 700th laser system just 4 years into being on the market. So we really appreciate the reception of our products and our technology. What we strive towards is building lasers that are more user friendly, more compact, more affordable, and therefore allows ophthalmologists to operate more efficiently to the benefit of them and their patients. So we're really excited to be here and we look forward to seeing you at the show.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.